David S Goldstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5128990/publications.pdf

Version: 2024-02-01

424 papers

37,505 citations

89 h-index 173 g-index

431 all docs

431 docs citations

times ranked

431

38483 citing authors

#	Article	IF	CITATIONS
1	The mutational constraint spectrum quantified from variation in 141,456 humans. Nature, 2020, 581, 434-443.	13.7	6 ,1 40
2	Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clinical Autonomic Research, 2011, 21, 69-72.	1.4	1,231
3	Biochemical Diagnosis of Pheochromocytoma. JAMA - Journal of the American Medical Association, 2002, 287, 1427-34.	3.8	994
4	Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine. Pharmacological Reviews, 2004, 56, 331-349.	7.1	849
5	Takotsubo Cardiomyopathy. Circulation, 2008, 118, 2754-2762.	1.6	735
6	Low-frequency power of heart rate variability is not a measure of cardiac sympathetic tone but may be a measure of modulation of cardiac autonomic outflows by baroreflexes. Experimental Physiology, 2011, 96, 1255-1261.	0.9	623
7	Frequency and the conference of referential validity. Journal of Verbal Learning and Verbal Behavior, 1977, 16, 107-112.	3.8	589
8	Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. Annals of Internal Medicine, 2001, 134, 315.	2.0	512
9	Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Autonomic Neuroscience: Basic and Clinical, 2011, 161, 46-48.	1.4	470
10	II. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sciences, 1981, 28, 467-475.	2.0	450
11	Biochemical Diagnosis of Pheochromocytoma: How to Distinguish True- from False-Positive Test Results. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2656-2666.	1.8	447
12	Cardiac Sympathetic Nerve Function in Congestive Heart Failure. Circulation, 1996, 93, 1667-1676.	1.6	376
13	Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Annals of Neurology, 2011, 69, 570-580.	2.8	371
14	Sources and Significance of Plasma Levels of Catechols and Their Metabolites in Humans. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 800-811.	1.3	355
15	Stress-Induced Norepinephrine Release in the Hypothalamic Paraventricular Nucleus and Pituitary-Adrenocortical and Sympathoadrenal Activity: In Vivo Microdialysis Studies. Frontiers in Neuroendocrinology, 1995, 16, 89-150.	2.5	348
16	Plasma Normetanephrine and Metanephrine for Detecting Pheochromocytoma in von Hippel–Lindau Disease and Multiple Endocrine Neoplasia Type 2. New England Journal of Medicine, 1999, 340, 1872-1879.	13.9	335
17	Cardiac Sympathetic Denervation in Parkinson Disease. Annals of Internal Medicine, 2000, 133, 338.	2.0	312
18	Sympathetic Cardioneuropathy in Dysautonomias. New England Journal of Medicine, 1997, 336, 696-702.	13.9	309

#	Article	IF	CITATIONS
19	Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine-Related Cancer, 2004, 11, 423-436.	1.6	299
20	Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurology, The, 2003, 2, 669-676.	4.9	292
21	Low frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. Clinical Autonomic Research, 2011, 21, 133-141.	1.4	292
22	Neonatal Diagnosis and Treatment of Menkes Disease. New England Journal of Medicine, 2008, 358, 605-614.	13.9	269
23	Dopamine Biosynthesis Is Selectively Abolished in Substantia Nigra/Ventral Tegmental Area but Not in Hypothalamic Neurons in Mice with Targeted Disruption of the Nurr1 Gene. Molecular and Cellular Neurosciences, 1998, 11, 36-46.	1.0	268
24	Relative contribution of core and cutaneous temperatures to thermal comfort and autonomic responses in humans. Journal of Applied Physiology, 1999, 86, 1588-1593.	1.2	266
25	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008.	1.8	262
26	Allostasis, Homeostats, and the Nature of Stress. Stress, 2002, 5, 55-58.	0.8	262
27	Prevalence of orthostatic hypotension in Parkinson's disease: A systematic review and meta-analysis. Parkinsonism and Related Disorders, 2011, 17, 724-729.	1.1	259
28	Responses of the Hypothalamic-Pituitary-Adrenal and Renin-Angiotensin Axes and the Sympathetic System During Controlled Surgical and Anesthetic Stress. Journal of Clinical Endocrinology and Metabolism, 1987, 64, 986-994.	1.8	257
29	Occipital horn syndrome and a mild Menkes phenotype associated with splice site mutations at the MNK locus. Nature Genetics, 1994, 8, 195-202.	9.4	244
30	Evolution of concepts of stress, 2007, 10, 109-120.	0.8	244
31	Natural history of pure autonomic failure: A <scp>U</scp> nited <scp>S</scp> tates prospective cohort. Annals of Neurology, 2017, 81, 287-297.	2.8	229
32	Cardiovascular dysautonomia in Parkinson disease: From pathophysiology to pathogenesis. Neurobiology of Disease, 2012, 46, 572-580.	2.1	227
33	Time of day, intellectual performance, and behavioral problems in Morning versus Evening type adolescents: Is there a synchrony effect?. Personality and Individual Differences, 2007, 42, 431-440.	1.6	225
34	Phosphorylated α-Synuclein in Parkinson's Disease. Science Translational Medicine, 2012, 4, 121ra20.	5.8	223
35	6-[¹⁸ F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma. Hypertension, 2001, 38, 6-8.	1.3	215
36	Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1994, 653, 131-138.	1.7	213

3

#	Article	IF	CITATIONS
37	Biochemical and Clinical Manifestations of Dopamine-Producing Paragangliomas: Utility of Plasma Methoxytyramine. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2068-2075.	1.8	213
38	Reversibility of Catecholamine-Induced Dilated Cardiomyopathy in a Child with a Pheochromocytoma. New England Journal of Medicine, 1987, 316, 793-797.	13.9	203
39	Association Between Supine Hypertension and Orthostatic Hypotension in Autonomic Failure. Hypertension, 2003, 42, 136-142.	1.3	203
40	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
41	A New Glucocerebrosidase Chaperone Reduces Â-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. Journal of Neuroscience, 2016, 36, 7441-7452.	1.7	189
42	Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free Metanephrines. Clinical Chemistry, 2005, 51, 735-744.	1.5	177
43	Orthostatic hypotension as an early finding in Parkinson's disease. Clinical Autonomic Research, 2006, 16, 46-54.	1.4	176
44	Adrenal Responses to Stress. Cellular and Molecular Neurobiology, 2010, 30, 1433-1440.	1.7	176
45	Supine low-frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. Heart Rhythm, 2007, 4, 1523-1529.	0.3	175
46	Functional corticotropin releasing factor receptors in the primate peripheral sympathetic nervous system. Nature, 1986, 319, 147-150.	13.7	171
47	Norepinephrine Precursor Therapy in Neurogenic Orthostatic Hypotension. Circulation, 2003, 108, 724-728.	1.6	169
48	Determinants of buildup of the toxic dopamine metabolite <scp>DOPAL</scp> in Parkinson's disease. Journal of Neurochemistry, 2013, 126, 591-603.	2.1	169
49	Conditional Expression of Parkinson's Disease-Related Mutant Â-Synuclein in the Midbrain Dopaminergic Neurons Causes Progressive Neurodegeneration and Degradation of Transcription Factor Nuclear Receptor Related 1. Journal of Neuroscience, 2012, 32, 9248-9264.	1.7	165
50	Patterns of plasma levels of catechols in neurogenic orthostatic hypotension. Annals of Neurology, 1989, 26, 558-563.	2.8	164
51	Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 9977-9982.	3.3	160
52	Catecholamines and their metabolites. Biomedical Applications, 1988, 429, 177-233.	1.7	156
53	Neurogenic Orthostatic Hypotension. Circulation, 2009, 119, 139-146.	1.6	154
54	Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies. Annals of Neurology, 2018, 83, 522-531.	2.8	150

#	Article	IF	CITATIONS
55	Neurodegeneration and Motor Dysfunction in Mice Lacking Cytosolic and Mitochondrial Aldehyde Dehydrogenases: Implications for Parkinson's Disease. PLoS ONE, 2012, 7, e31522.	1.1	142
56	Effects of Various Stressors on In Vivo Norepinephrine Release in the Hypothalamic Paraventricular Nucleus and on the Pituitary-Adrenocortical Axis. Annals of the New York Academy of Sciences, 1995, 771, 115-130.	1.8	141
57	Children's time of day preference: age, gender and ethnic differences. Personality and Individual Differences, 2002, 33, 1083-1090.	1.6	138
58	Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology. American Journal of Cardiology, 1981, 48, 1147-1154.	0.7	136
59	Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism and Related Disorders, 2008, 14, 600-607.	1.1	135
60	Laparoscopic Correction of Vesicoureteral Reflux. Journal of Urology, 1993, 150, 748-751.	0.2	134
61	Sympathetically mediated effects of mental stress on the cardiac microcirculation of patients with coronary artery disease. American Journal of Cardiology, 1995, 76, 125-130.	0.7	131
62	Association between cardiac denervation and parkinsonism caused by αâ€synuclein gene triplication. Brain, 2004, 127, 768-772.	3.7	131
63	Age-related thermoregulatory differences during core cooling in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 279, R349-R354.	0.9	130
64	Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders., 2014, 144, 268-282.		129
65	The Effect of Clozapine on Plasma Norepinephrine: Relationship to Clinical Efficacy. Neuropsychopharmacology, 1994, 10, 1-7.	2.8	125
66	Neurocirculatory Abnormalities in Parkinson Disease With Orthostatic Hypotension. Hypertension, 2005, 46, 1333-1339.	1.3	123
67	Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology, 2012, 79, 1323-1331.	1.5	121
68	Dysautonomia in Parkinson Disease. , 2014, 4, 805-826.		120
69	Heterogeneous neurochemical responses to different stressors: a test of Selye's doctrine of nonspecificity. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 275, R1247-R1255.	0.9	119
70	Adrenomedullary, adrenocortical, and sympathoneural responses to stressors: a meta-analysis. Endocrine Regulations, 2008, 42, 111-9.	0.5	118
71	Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. Brain, 2012, 135, 1900-1913.	3.7	115
72	Exaggerated Adrenomedullary Response to Immobilization in Mice with Targeted Disruption of the Serotonin Transporter Gene. Endocrinology, 2002, 143, 4520-4526.	1.4	113

#	Article	IF	Citations
73	Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1. Autonomic Neuroscience: Basic and Clinical, 2021, 235, 102828.	1.4	113
74	Oral Yohimbine Increases Blood Pressure and Sympathetic Nervous Outflow in Hypertensive Patients. Journal of Cardiovascular Pharmacology, 1993, 22, 22-26.	0.8	112
75	Catechols in post-mortem brain of patients with Parkinson disease. European Journal of Neurology, 2011, 18, 703-710.	1.7	111
76	Noradrenergic activation in the paraventricular nucleus during acute and chronic immobilization stress in rats: an in vivo microdialysis study. Brain Research, 1992, 589, 91-96.	1.1	110
77	Morphine Inhibits the Pituitary-Adrenal Response to Ovine Corticotropin-Releasing Hormone in Normal Subjects*. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 891-895.	1.8	109
78	The possible association between COVID-19 and postural tachycardia syndrome. Heart Rhythm, 2021, 18, 508-509.	0.3	109
79	Positron emission tomographic imaging of cardiac sympathetic Innervation using 6-[18 F]Fluorodopamine: Initial findings in humans. Journal of the American College of Cardiology, 1993, 22, 1961-1971.	1.2	106
80	Circulatory control mechanisms in vasodepressor syncope. American Heart Journal, 1982, 104, 1071-1075.	1.2	105
81	Baroreflex Failure as a Late Sequela of Neck Irradiation. Hypertension, 2003, 42, 110-116.	1.3	105
82	Plasma and cerebrospinal fluid neurochemical pattern in Menkes disease. Annals of Neurology, 1993, 33, 171-175.	2.8	101
83	Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in an animal model*. Critical Care Medicine, 2005, 33, 1311-1316.	0.4	99
84	Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease. Journal of the Neurological Sciences, 2011, 310, 123-128.	0.3	99
85	Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy. American Journal of Pathology, 2011, 178, 1509-1516.	1.9	97
86	Source and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. Journal of the Autonomic Nervous System, 1988, 24, 1-14.	1.9	96
87	Relative contribution of core and skin temperatures to thermal comfort in humans. Journal of Thermal Biology, 2000, 25, 147-150.	1.1	96
88	Cardiac Sympathetic Dysautonomia in Chronic Orthostatic Intolerance Syndromes. Circulation, 2002, 106, 2358-2365.	1.6	96
89	Corticotropin-releasing factor (CRF) produces analgesia in humans and rats. Brain Research, 1987, 422, 154-157.	1.1	95
90	Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biological Psychiatry, 1999, 46, 756-765.	0.7	95

#	Article	IF	Citations
91	Sources and Physiological Significance of Plasma Dopamine Sulfate. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2523-2531.	1.8	95
92	Progressive loss of cardiac sympathetic innervation in Parkinson's disease. Annals of Neurology, 2002, 52, 220-223.	2.8	93
93	The extended autonomic system, dyshomeostasis, and COVID-19. Clinical Autonomic Research, 2020, 30, 299-315.	1.4	93
94	Effects of immobilization on in vivo release of norepinephrine in the bed nucleus of the stria terminalis in conscious rats. Brain Research, 1995, 688, 242-246.	1.1	92
95	Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8303-8308.	3.3	90
96	The Role of Interferon in Cancer Therapy: A Current Perspective. Ca-A Cancer Journal for Clinicians, 1988, 38, 258-277.	157.7	89
97	Neuronal Source of Plasma Dihydroxyphenylalanine. Journal of Clinical Endocrinology and Metabolism, 1987, 64, 856-861.	1.8	88
98	Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clinical Autonomic Research, 2007, 17, 118-121.	1.4	88
99	Circadian rhythms in executive function during the transition to adolescence: the effect of synchrony between chronotype and time of day. Developmental Science, 2012, 15, 408-416.	1.3	88
100	L-Dihydroxyphenylserine (L-DOPS): A Norepinephrine Prodrug. Cardiovascular Drug Reviews, 2006, 24, 189-203.	4.4	87
101	Plasma and urinary catechllamines during the human ovulatory cycle. American Journal of Obstetrics and Gynecology, 1983, 146, 824-829.	0.7	86
102	Derivation of Urinary Dopamine from Plasma Dihydroxyphenylalanine in Humans. Clinical Science, 1993, 84, 549-557.	1.8	86
103	Stress-induced activation of the sympathetic nervous system. Bailliere's Clinical Endocrinology and Metabolism, 1987, 1, 253-278.	1.0	85
104	Survival in synucleinopathies. Neurology, 2015, 85, 1554-1561.	1.5	84
105	Catecholamines and stress. Endocrine Regulations, 2003, 37, 69-80.	0.5	84
106	Radiofrequency Ablation: a Novel Approach for Treatment of Metastatic Pheochromocytoma. Journal of the National Cancer Institute, 2001, 93, 648-649.	3.0	83
107	Catecholamines 101. Clinical Autonomic Research, 2010, 20, 331-352.	1.4	80
108	Impaired Basal and Restraint-Induced Epinephrine Secretion in Corticotropin-Releasing Hormone-Deficient Mice ¹ . Endocrinology, 2000, 141, 1142-1150.	1.4	78

#	Article	IF	CITATIONS
109	Autonomic dysfunction in Parkinson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 117, 259-278.	1.0	76
110	Urinary excretion rate of endothelin-1 in patients with essential hypertension and salt sensitivity. Kidney International, 1994, 45, 556-560.	2.6	74
111	Early copper therapy in classic Menkes disease patients with a novel splicing mutation. Annals of Neurology, 1995, 38, 921-928.	2.8	74
112	Coexpression of Tyrosine Hydroxylase, GTP Cyclohydrolase I, Aromatic Amino Acid Decarboxylase, and Vesicular Monoamine Transporter 2 from a Helper Virus-Free Herpes Simplex Virus Type 1 Vector Supports High-Level, Long-Term Biochemical and Behavioral Correction of a Rat Model of Parkinson's Disease. Human Gene Therapy, 2004, 15, 1177-1196.	1.4	74
113	Neuronal Source of Plasma Dopamine. Clinical Chemistry, 2008, 54, 1864-1871.	1.5	74
114	Biofeedback heart rate training during exercise. Biofeedback and Self-regulation, 1977, 2, 107-125.	0.3	73
115	Is There a Third Peripheral Catecholaminergic System? Endogenous Dopamine as an Autocrine/Paracrine Substance Derived from Plasma DOPA and Inactivated by Conjugation. Hypertension Research, 1995, 18, S93-S99.	1.5	69
116	Clonidine Suppression Testing in Essential Hypertension. Annals of Internal Medicine, 1985, 102, 42.	2.0	68
117	Inhibition of Peritoneal Tumor-Cell Implantation: Model for Laparoscopic Cancer Surgery. Journal of Endourology, 1993, 7, 237-241.	1.1	68
118	Generalized and neurotransmitterâ€selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension. Movement Disorders, 2008, 23, 1725-1732.	2.2	68
119	Autonomic uprising: the tilt table test in autonomic medicine. Clinical Autonomic Research, 2019, 29, 215-230.	1.4	68
120	Cognition of arousal and actual arousal as determinants of emotion Journal of Personality and Social Psychology, 1972, 21, 41-51.	2.6	66
121	Effects of Handling or Immobilization on Plasma Levels of 3,4-Dihydroxyphenylalanine, Catecholamines, and Metabolites in Rats. Journal of Neurochemistry, 1992, 58, 2296-2302.	2.1	65
122	Bacillus calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology, 1996, 48, 957-962.	0.5	65
123	Vesicular uptake blockade generates the toxic dopamine metabolite 3,4â€dihydroxyphenylacetaldehyde in <scp>PC</scp> 12 cells: relevance to the pathogenesis of Parkinson's disease. Journal of Neurochemistry, 2012, 123, 932-943.	2.1	65
124	Catecholamine-glucocorticoid interactions during surgical stress. Journal of Surgical Research, 1987, 43, 539-545.	0.8	64
125	Urinary excretion of dihydroxyphenylalanine and dopamine during alterations of dietary salt intake in humans. Clinical Science, 1989, 76, 517-522.	1.8	64
126	Effects of Single or Repeated Immobilization on Release of Norepinephrine and Its Metabolites in the Central Nucleus of the Amygdala in Conscious Rats. Neuroendocrinology, 1993, 57, 626-633.	1.2	64

#	Article	IF	CITATIONS
127	Interrelations between Sympathoadrenal System and Hypothalamo-Pituitary-Adrenocortical/Thyroid Systemsin Rats Exposed to Cold Stress. Journal of Neuroendocrinology, 1996, 8, 533-541.	1.2	64
128	Adrenergic and Endothelin B Receptor-Dependent Hypertension in Dopamine Receptor Type-2 Knockout Mice. Hypertension, 2001, 38, 303-308.	1.3	64
129	Sympathoadrenal imbalance before neurocardiogenic syncope. American Journal of Cardiology, 2003, 91, 53-58.	0.7	64
130	Autonomic dysfunction in PD: A window to early detection?. Journal of the Neurological Sciences, 2011, 310, 118-122.	0.3	64
131	ATP7A Gene Addition to the Choroid Plexus Results in Long-term Rescue of the Lethal Copper Transport Defect in a Menkes Disease Mouse Model. Molecular Therapy, 2011, 19, 2114-2123.	3.7	64
132	Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. Journal of Clinical Investigation, 2011, 121, 3320-3330.	3.9	64
133	Plasma dihydroxyphenylglycol for estimation of noradrenaline neuronal re-uptake in the sympathetic nervous system in vivo. Clinical Science, 1989, 76, 171-182.	1.8	63
134	Prothrombotic Effects of Environmental Stress. Psychosomatic Medicine, 1995, 57, 592-599.	1.3	63
135	Sympathoneural and Adrenomedullary Responses to Mental Stress. , 2015, 5, 119-146.		63
136	Naloxone, fentanyl, and diazepam modify plasma beta-endorphin levels during surgery. Clinical Pharmacology and Therapeutics, 1986, 40, 165-171.	2.3	62
137	Correction of a Rat Model of Parkinson's Disease by Coexpression of Tyrosine Hydroxylase and Aromatic Amino Acid Decarboxylase from a Helper Virus-Free Herpes Simplex Virus Type 1 Vector. Human Gene Therapy, 2003, 14, 415-424.	1.4	62
138	Derivation of urinary dopamine from plasma dopa. Clinical Science, 1988, 75, 515-520.	1.8	61
139	Successful Early Copper Therapy in Menkes Disease Associated with a Mutant Transcript Containing a Small In-Frame Deletion. Biochemical and Molecular Medicine, 1996, 57, 37-46.	1.5	61
140	Noninvasive detection of sympathetic neurocirculatory failure. Clinical Autonomic Research, 2000, 10, 285-291.	1.4	61
141	Pheochromocytoma: Rediscovery as a catecholamine-metabolizing tumor. Endocrine Pathology, 2003, 14, 193-212.	5.2	61
142	Age differences in choice satisfaction: A positivity effect in decision making Psychology and Aging, 2008, 23, 33-38.	1.4	61
143	Cardiac denervation in patients with Parkinson disease Cleveland Clinic Journal of Medicine, 2007, 74, S91-S91.	0.6	61
144	Steady-state dopamine clearance in critically ill infants and children. Critical Care Medicine, 1988, 16, 217-220.	0.4	60

#	Article	IF	Citations
145	Diagnostic Localization of Pheochromocytoma. Annals of the New York Academy of Sciences, 2002, 970, 170-176.	1.8	60
146	Cardiac and extracardiac sympathetic denervation in Parkinson's disease with orthostatic hypotension and in pure autonomic failure. Journal of Nuclear Medicine, 2005, 46, 1775-81.	2.8	60
147	Olfactory dysfunction in pure autonomic failure: Implications for the pathogenesis of Lewy body diseases. Parkinsonism and Related Disorders, 2009, 15, 516-520.	1.1	59
148	Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein. Neuroscience Letters, 2014, 569, 27-32.	1.0	59
149	Increased myocardial perfusion and sympathoadrenal activation during mild core hypothermia in awake humans. Clinical Science, 2003, 104, 503-508.	1.8	58
150	Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology, 2014, 76, 97-105.	2.0	58
151	Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. European Journal of Endocrinology, 2005, 153, 551-563.	1.9	57
152	Mechanism of Peripheral Noradrenergic Stimulation by Clozapine. Neuropsychopharmacology, 1999, 20, 29-34.	2.8	56
153	Sympathetic innervation and function in reflex sympathetic dystrophy. Annals of Neurology, 2000, 48, 49-59.	2.8	56
154	Association of anosmia with autonomic failure in Parkinson disease. Neurology, 2010, 74, 245-251.	1.5	56
155	Endocrine, Renal, and Hemodynamic Responses to Graded Dopamine Infusions in Normal Men. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 821-826.	1.8	55
156	Levels of Catechols in Epileptogenic and Nonepileptogenic Regions of the Human Brain. Journal of Neurochemistry, 1988, 50, 225-229.	2.1	55
157	Benomyl, Aldehyde Dehydrogenase, DOPAL, and the Catecholaldehyde Hypothesis for the Pathogenesis of Parkinson's Disease. Chemical Research in Toxicology, 2014, 27, 1359-1361.	1.7	55
158	Beat-to-beat blood pressure and heart rate responses to the Valsalva maneuver. Clinical Autonomic Research, 2017, 27, 361-367.	1.4	55
159	Mechanisms of Chronotropic Incompetence in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006331.	1.6	52
160	A "Pheo―Lurks: Novel Approaches for Locating Occult Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3641-3646.	1.8	51
161	Dihydrocaffeic acid: a common contaminant in the liquid chromatographic-electrochemical measurement of plasma catecholamines in man. Biomedical Applications, 1984, 311, 148-153.	1.7	49
162	Plasma 3, 4-Dihydroxyphenylalanine (Dopa) and Catecholamines in Neuroblastoma or Pheochromocytoma. Annals of Internal Medicine, 1986, 105, 887.	2.0	49

#	Article	IF	Citations
163	Angiotensin II increases cytosolic calcium and stimulates catecholamine release in cultured bovine adrenomedullary cells. Cell Calcium, 1987, 8, 315-325.	1.1	49
164	Pandysautonomia associated with impaired ganglionic neurotransmission and circulating antibody to the neuronal nicotinic receptor. Clinical Autonomic Research, 2002, 12, 281-285.	1.4	49
165	Leaky Catecholamine Stores: Undue Waste or a Stress Response Coping Mechanism?. Annals of the New York Academy of Sciences, 2004, 1018, 224-230.	1.8	49
166	Glucocorticoid-induced sympathoinhibition in humans. Clinical Pharmacology and Therapeutics, 1995, 58, 90-98.	2.3	48
167	Simultaneous measurement of plasma and brain extracellular fluid concentrations of catechols after yohimbine administration in rats. Brain Research, 1991, 542, 8-14.	1.1	47
168	Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clinical Autonomic Research, 2004, 14, 363-368.	1.4	47
169	Regional extraction of circulating norepinephrine, DOPA, and dihydroxyphenylglycol in humans. Journal of the Autonomic Nervous System, 1991, 34, 17-35.	1.9	46
170	Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans. Biological Psychiatry, 1992, 32, 880-890.	0.7	46
171	3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells. Neurochemical Research, 2016, 41, 2173-2178.	1.6	46
172	Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in man. Psychopharmacology, 1984, 84, 200-204.	1.5	45
173	Plasma Dihydroxyphenylalanine and Total Body and Regional Noradrenergic Activity in Humans. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 247-255.	1.8	45
174	The heart of PD: Lewy body diseases as neurocardiologic disorders. Brain Research, 2019, 1702, 74-84.	1.1	45
175	Relative Efficiencies of Plasma Catechol Levels and Ratios for Neonatal Diagnosis of Menkes Disease. Neurochemical Research, 2009, 34, 1464-1468.	1.6	44
176	Differences in the Neuronal Removal of Circulating Epinephrine and Norepinephrine. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1710-1720.	1.8	43
177	Modulation of Rat Rotational Behavior by Direct Gene Transfer of Constitutively Active Protein Kinase C into Nigrostriatal Neurons. Journal of Neuroscience, 1998, 18, 4119-4132.	1.7	43
178	Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2000, 35, 1867-1873.	1.2	43
179	Impact of Chromogranin A deficiency on catecholamine storage, catecholamine granule morphology and chromaffin cell energy metabolism in vivo. Cell and Tissue Research, 2016, 363, 693-712.	1.5	43
180	How does homeostasis happen? Integrative physiological, systems biological, and evolutionary perspectives. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2019, 316, R301-R317.	0.9	43

#	Article	IF	Citations
181	Source and Physiological Significance of Plasma 3,4-Dihydroxyphenylalanine in the Rat. Journal of Neurochemistry, 1988, 51, 1204-1213.	2.1	42
182	Sympathoadrenomedullary Inhibition by Chronic Glucocorticoid Treatment in Conscious Rats. Endocrinology, 1988, 123, 2585-2590.	1.4	42
183	Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. Journal of Hypertension, 2007, 25, 2286-2295.	0.3	42
184	Chronic Hypercortisolemia Inhibits Dopamine Synthesis and Turnover in the Nucleus accumbens: An in vivo Microdialysis Study. Neuroendocrinology, 2002, 76, 148-157.	1.2	41
185	Supine low-frequency power of heart rate variability reflects baroreflex function, not cardiac sympathetic innervation. Cleveland Clinic Journal of Medicine, 2009, 76, S51-S59.	0.6	41
186	Plasma catecholamine and hemodynamic responses during isoproterenol infusions in humans. Clinical Pharmacology and Therapeutics, 1986, 40, 233-238.	2.3	40
187	Diagnosis and Localization of Pheochromocytoma. Hypertension, 2004, 43, 907-910.	1.3	40
188	Differences in ATP7A gene expression underlie intrafamilial variability in Menkes disease/occipital horn syndrome. Journal of Medical Genetics, 2007, 44, 492-497.	1.5	40
189	Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease. Parkinsonism and Related Disorders, 2018, 50, 108-112.	1.1	40
190	Thirty-Day Readmission Risk Model for Older Adults Hospitalized With Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005320.	0.9	40
191	Changes in coagulation parameters with exercise in patients with classic hemophilia. American Journal of Hematology, 1984, 16, 227-233.	2.0	39
192	The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. Journal of the Autonomic Nervous System, 1994, 50, 93-107.	1.9	39
193	Functional effects of cardiac sympathetic denervation in neurogenic orthostatic hypotension. Parkinsonism and Related Disorders, 2009, 15, 122-127.	1.1	39
194	Differential responses of components of the autonomic nervous system. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 117, 13-22.	1.0	39
195	Cerebrospinal Fluid and Serum Levels of DOPA, Catechols, and Monoamine Metabolites in Patients with Epilepsy. Epilepsia, 1992, 33, 263-270.	2.6	38
196	Pure autonomic failure. Neurology, 2010, 74, 536-537.	1.5	38
197	Positron emission imaging of cardiac sympathetic innervation and function using 18F-6-fluorodopamine: effects of chemical sympathectomy by 6-hydroxydopamine. Journal of Hypertension, 1991, 9, 417-423.	0.3	37
198	Glycine stimulates striatal dopamine release in conscious rats. British Journal of Pharmacology, 1993, 110, 50-53.	2.7	37

#	Article	IF	CITATIONS
199	Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 484-493.	1.3	37
200	Homeostatic systems, biocybernetics, and autonomic neuroscience. Autonomic Neuroscience: Basic and Clinical, 2017, 208, 15-28.	1.4	37
201	Effect of Ganglion Blockade on Cerebrospinal Fluid Norepinephrine. Journal of Neurochemistry, 1987, 49, 1484-1490.	2.1	36
202	Neurocirculatory Abnormalities in Chronic Orthostatic Intolerance. Circulation, 2005, 111, 839-845.	1.6	36
203	Central dopamine deficiency in pure autonomic failure. Clinical Autonomic Research, 2008, 18, 58-65.	1.4	36
204	Effects of two formats of informed consent on knowledge amongst persons with advanced HIV disease in a clinical trial of didanosine. Patient Education and Counseling, 1994, 24, 261-266.	1.0	35
205	Local Sympathetic Denervation in Painful Diabetic Neuropathy. Diabetes, 2002, 51, 3545-3553.	0.3	35
206	The catecholaldehyde hypothesis: where MAO fits in. Journal of Neural Transmission, 2020, 127, 169-177.	1.4	35
207	Sympathetic Innervation in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Primate Model of Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 855-860.	1.3	34
208	Autoimmune autonomic ganglionopathy: treatment by plasma exchanges and rituximab. Clinical Autonomic Research, 2009, 19, 259-262.	1.4	34
209	Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease. Journal of Neurochemistry, 2015, 133, 14-25.	2.1	34
210	3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by <i>N</i> -Acetylcysteine. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 113-124.	1.3	34
211	Cardiac sympathetic denervation predicts PD in at-risk individuals. Parkinsonism and Related Disorders, 2018, 52, 90-93.	1.1	34
212	Neuropharmacologic Distinction of Neurogenic Orthostatic Hypotension Syndromes. Clinical Neuropharmacology, 2006, 29, 97-105.	0.2	33
213	Does Expressive Writing Reduce Stress and Improve Health for Family Caregivers of Older Adults?. Gerontologist, The, 2007, 47, 296-306.	2.3	33
214	Sympathetic noradrenergic before striatal dopaminergic denervation: relevance to Braak staging of synucleinopathy. Clinical Autonomic Research, 2012, 22, 57-61.	1.4	33
215	Validity of liquid chromatography with electrochemical detection for measuring dopamine in human plasma. Clinica Chimica Acta, 1981, 117, 113-120.	0.5	31
216	Decreased sympathetic neuronal uptake in idiopathic orthostatic hypotension. Annals of Neurology, 1985, 18, 48-53.	2.8	31

#	Article	IF	Citations
217	Indices of sympathetic vascular innervation in sympathectomized patients. Journal of the Autonomic Nervous System, 1986, 15, 309-318.	1.9	31
218	Coping responses to HIVâ€1 serostatus notification predict concurrent and prospective immunologic status. Clinical Psychology and Psychotherapy, 1995, 2, 234-248.	1.4	31
219	Brainstem Hemisection Decreases Corticotropin-Releasing Hormone mRNA in the Paraventricular Nucleus but not in the Central Amygdaloid Nucleus. Journal of Neuroendocrinology, 1996, 8, 543-551.	1.2	31
220	Gender Differences in Brain Metabolic and Plasma Catecholamine Responses to Alpha2-Adrenoceptor Blockade. Neuropsychopharmacology, 1997, 16, 298-310.	2.8	31
221	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <scp>Movement Disorder Society</scp> Multiple System Atrophy Study Group. Movement Disorders Clinical Practice, 2020, 7, 750-762.	0.8	31
222	Role of CRH in Glucopenia-Induced Adrenomedullary Activation in Rats. Journal of Neuroendocrinology, 1993, 5, 475-486.	1.2	30
223	Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration. Parkinsonism and Related Disorders, 2015, 21, 1013-1022.	1.1	30
224	3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing $\langle i \rangle \hat{1} \pm \langle i \rangle$ -Synuclein. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 157-165.	1.3	30
225	Postural orthostatic tachycardia syndrome (POTS): Priorities for POTS care and research from a 2019 National Institutes of Health Expert Consensus Meeting – Part 2. Autonomic Neuroscience: Basic and Clinical, 2021, 235, 102836.	1.4	30
226	Meta-analysis of nonselective versus beta-1 adrenoceptor-selective blockade in prevention of tilt-induced neurocardiogenic syncope. American Journal of Cardiology, 2002, 89, 1319-1321.	0.7	29
227	Sympathoadrenal contribution to plasma dopa (3,4-dihydroxyphenylalanine) in rats. Clinical Science, 1992, 83, 65-74.	1.8	28
228	Prostate cancer screening: Role of digital rectal examination and prostate-specific antigen. Annals of Surgical Oncology, 1994, 1, 117-120.	0.7	28
229	Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. British Journal of Haematology, 1997, 97, 38-45.	1.2	28
230	Plasma catecholamines and blood volume in native Andeans during hypoxia and normoxia. Clinical Autonomic Research, 2006, 16, 40-45.	1.4	28
231	Biomarkers, Mechanisms, and Potential Prevention of Catecholamine Neuron Loss in Parkinson Disease. Advances in Pharmacology, 2013, 68, 235-272.	1.2	28
232	Alpha-Synuclein Deposition Within Sympathetic Noradrenergic Neurons Is Associated With Myocardial Noradrenergic Deficiency in Neurogenic Orthostatic Hypotension. Hypertension, 2019, 73, 910-918.	1.3	28
233	Sympathetic Neurocirculatory Failure in Parkinson Disease: Evidence for an Etiologic Role of α-Synuclein. Annals of Internal Medicine, 2001, 135, 1010.	2.0	28
234	Stressor-Specific Activation of Catecholaminergic Systems: Implications for Stress-Related Hypothalamic-Pituitary-Adrenocortical Responses. Advances in Pharmacology, 1997, 42, 561-564.	1.2	27

#	Article	IF	Citations
235	α2-Adrenoceptor-mediated restraint of norepinephrine synthesis, release, and turnover during immobilization in rats. Brain Research, 1999, 826, 243-252.	1.1	27
236	Low Sensitivity of Glucagon Provocative Testing for Diagnosis of Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 238-245.	1.8	27
237	Concepts of Scientific Integrative Medicine Applied to the Physiology and Pathophysiology of Catecholamine Systems., 2013, 3, 1569-1610.		27
238	A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease. Journal of Neurochemistry, 2014, 131, 219-228.	2.1	27
239	Predominant Glandular Cholinergic Dysautonomia in Patients With Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2015, 67, 1345-1352.	2.9	27
240	Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies. Parkinsonism and Related Disorders, 2016, 31, 79-86.	1.1	27
241	Effects of Continuous and Intermittent Cold (SART) Stress on Sympathoadrenal System Activity in Rats. Journal of Neuroendocrinology, 1996, 8, 65-72.	1.2	26
242	Stimulation of the paraventricular nucleus modulates firing of neurons in the nucleus of the solitary tract. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1999, 277, R403-R411.	0.9	26
243	Effect of systemic alpha-2 adrenergic blockade on the morning increase in platelet aggregation in normal subjects. American Journal of Cardiology, 1999, 84, 316-320.	0.7	26
244	Threshold for adrenomedullary activation and increased cardiac work during mild core hypothermia. Clinical Science, 2002, 102, 119.	1.8	26
245	Determinants of denervation-independent depletion of putamen dopamine in Parkinson's disease and multiple system atrophy. Parkinsonism and Related Disorders, 2017, 35, 88-91.	1.1	26
246	Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky. Cellular and Molecular Neurobiology, 2018, 38, 13-24.	1.7	26
247	Sympathoadrenal excitation and inhibition by lower brainstem stimulation in cats. Journal of the Autonomic Nervous System, 1991, 33, 35-46.	1.9	25
248	Different relationships of spillover to release of norepinephrine in human heart, kidneys, and forearm. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 275, R165-R173.	0.9	25
249	Computer Models of Stress, Allostasis, and Acute and Chronic Diseases. Annals of the New York Academy of Sciences, 2008, 1148, 223-231.	1.8	25
250	Clinical laboratory evaluation of autoimmune autonomic ganglionopathy: Preliminary observations. Autonomic Neuroscience: Basic and Clinical, 2009, 146, 18-21.	1.4	25
251	Effects of Carbidopa and Entacapone on the Metabolic Fate of the Norepinephrine Prodrug L-DOPS. Journal of Clinical Pharmacology, 2011, 51, 66-74.	1.0	25
252	Plasma levels of catecholamines and corticotrophin during acute glucopenia induced by 2-deoxy-D-glucose in normal man. Clinical Autonomic Research, 1992, 2, 359-366.	1.4	24

#	Article	IF	Citations
253	Catechol-O-Methyltransferase and Blood Pressure in Humans. Circulation, 2002, 106, 460-465.	1.6	24
254	Effects of Risperidone on the Peripheral Noradrenegic System in Patients with Schizophrenia A Comparison with Clozapine and Placebo. Neuropsychopharmacology, 2002, 27, 293-300.	2.8	24
255	Transcriptional Regulation of Phenylethanolamine N-Methyltransferase in Pheochromocytomas from Patients with von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2. Annals of the New York Academy of Sciences, 2006, 1073, 241-252.	1.8	24
256	The autonomic medical history. Clinical Autonomic Research, 2017, 27, 223-233.	1.4	24
257	N-Acetylcysteine Prevents the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells. Neurochemical Research, 2017, 42, 3289-3295.	1.6	24
258	Roles of catechol neurochemistry in autonomic function testing. Clinical Autonomic Research, 2018, 28, 273-288.	1.4	24
259	Aging-related changes in cardiac sympathetic function in humans, assessed by 6-18F-fluorodopamine PET scanning. Journal of Nuclear Medicine, 2003, 44, 1599-603.	2.8	24
260	Sympathoadrenomedullary hyper-responsiveness to yohimbine in juvenile spontaneously hypertensive rats. Life Sciences, 1988, 43, 1063-1068.	2.0	23
261	Altered norepinephrine regulation in bulimia: Effects of pharmacological challenge with isoproterenol. Psychiatry Research, 1990, 33, 1-10.	1.7	23
262	Threshold for adrenomedullary activation and increased cardiac work during mild core hypothermia. Clinical Science, 2002, 102, 119-125.	1.8	23
263	In utero copper treatment for Menkes disease associated with a severe ATP7A mutation. Molecular Genetics and Metabolism, 2012, 107, 222-228.	0.5	23
264	Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Cleveland Clinic Journal of Medicine, 2009, 76, S47-S50.	0.6	23
265	Modified sample preparation for high-performance liquid chromatographic—electrochemical assay of urinary catecholamines. Biomedical Applications, 1983, 275, 174-177.	1.7	22
266	Pressor and depressor responses after cholinergic blockade in humans. American Heart Journal, 1984, 107, 974-979.	1.2	22
267	Clinical Assessment of Sympathetic Responses to Stress. Annals of the New York Academy of Sciences, 1995, 771, 570-593.	1.8	22
268	Sympathetic neuroimaging. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 117, 365-370.	1.0	22
269	Enhanced tyrosine hydroxylase activity induces oxidative stress, causes accumulation of autotoxic catecholamine metabolites, and augments amphetamine effects in vivo. Journal of Neurochemistry, 2021, 158, 960-979.	2.1	22
270	Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases. JCI Insight, 2019, 4, .	2.3	22

#	Article	IF	CITATIONS
271	Differential Effects of Low- and High-Intensity Lower Body Negative Pressure on Noradrenaline and Adrenaline Kinetics in Humans. Clinical Science, 1996, 90, 337-343.	1.8	21
272	Differential effects of chemical sympathectomy on expression and activity of tyrosine hydroxylase and levels of catecholamines and DOPA in peripheral tissues of rats. Neurochemical Research, 1999, 24, 25-32.	1.6	21
273	Inverse relationship between plasma epinephrine and testosterone levels during acute glucoprivation in healthy men. Life Sciences, 2001, 68, 1889-1898.	2.0	21
274	Cardiac sympathetic hypo-innervation in familial dysautonomia. Clinical Autonomic Research, 2008, 18, 115-119.	1.4	21
275	Seeing the glass half full: Optimistic expressive writing improves mental health among chronically stressed caregivers. British Journal of Health Psychology, 2008, 13, 73-76.	1.9	21
276	Pure autonomic failure without synucleinopathy. Clinical Autonomic Research, 2017, 27, 97-101.	1.4	21
277	Long-term trends in myocardial sympathetic innervation and function in synucleinopathies. Parkinsonism and Related Disorders, 2019, 67, 27-33.	1.1	21
278	Contributions of Benzodiazepines to Cancer Therapy. Cancer Investigation, 1988, 6, 103-111.	0.6	20
279	Monoaminergic effects of high-dose corticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus. Movement Disorders, 1998, 13, 522-528.	2.2	20
280	A Test of the "Epinephrine Hypothesis―in Humans. Hypertension, 1999, 33, 36-43.	1.3	20
281	Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy. Parkinsonism and Related Disorders, 2015, 21, 567-572.	1.1	20
282	The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know. International Journal of Molecular Sciences, 2021, 22, 5999.	1.8	20
283	Sources and Physiological Significance of Plasma Dopamine Sulfate. , 0, .		20
284	Stress and the "extended―autonomic system. Autonomic Neuroscience: Basic and Clinical, 2021, 236, 102889.	1.4	20
285	The physical examination as a window into autonomic disorders. Clinical Autonomic Research, 2018, 28, 23-33.	1.4	19
286	Inhibition of hormone-dependent and independent breast cancer cell growthin vivo andin vitro with the antiestrogen toremifene and recombinant human interferon-α2. Breast Cancer Research and Treatment, 1990, 15, 95-101.	1.1	18
287	Partial cardiac sympathetic denervation after bilateral thoracic sympathectomy in humans. Heart Rhythm, 2005, 2, 602-609.	0.3	18
288	Stress, Allostatic Load, Catecholamines, and Other Neurotransmitters in Neurodegenerative Diseases. Cellular and Molecular Neurobiology, 2012, 32, 661-666.	1.7	18

#	Article	IF	CITATIONS
289	Cardiac Dysautonomia and Survival in Hereditary Transthyretin Amyloidosis â^—. JACC: Cardiovascular Imaging, 2016, 9, 1442-1445.	2.3	18
290	DOPAL is transmissible to and oligomerizes alpha-synuclein in human glial cells. Autonomic Neuroscience: Basic and Clinical, 2016, 194, 46-51.	1.4	18
291	Cardiac ectopy in chronic autonomic failure. Clinical Autonomic Research, 2010, 20, 85-92.	1.4	17
292	Roles of cardiac sympathetic neuroimaging in autonomic medicine. Clinical Autonomic Research, 2018, 28, 397-410.	1.4	17
293	Research Opportunities in Autonomic Neural Mechanisms of CardiopulmonaryÂRegulation. JACC Basic To Translational Science, 2022, 7, 265-293.	1.9	17
294	Epinephrine Suppresses Stress-Induced Increases in Plasma Immunoreactive \hat{l}^2 -Endorphin in Humans. Journal of Clinical Endocrinology and Metabolism, 1989, 69, 546-551.	1.8	16
295	Plasma levels of catechols during reflexive changes in sympathetic nerve activity. Neurochemical Research, 1989, 14, 523-531.	1.6	16
296	Cardiac sympathetic neuroimaging to distinguish multiple system atrophy from Parkinson disease. Clinical Autonomic Research, 2001, 11, 341-342.	1.4	16
297	Kinetic model for the fate of 6-[18 F]fluorodopamine in the human heart: a novel means to examine cardiac sympathetic neuronal function. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 365, 38-49.	1.4	16
298	Imaging of the Autonomic Nervous System: Focus on Cardiac Sympathetic Innervation. Seminars in Neurology, 2003, 23, 423-434.	0.5	16
299	Neurocardiology: Therapeutic Implications for Cardiovascular Disease. Cardiovascular Therapeutics, 2012, 30, e89-106.	1.1	16
300	Autoimmunity-associated autonomic failure with sympathetic denervation. Clinical Autonomic Research, 2017, 27, 57-62.	1.4	16
301	Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies. Annals of Clinical and Translational Neurology, 2020, 7, 2450-2460.	1.7	16
302	Neuroscience and heart-brain medicine: The year in review. Cleveland Clinic Journal of Medicine, 2010, 77, S34-S39.	0.6	16
303	Prolonged Interleukin-2 (IL-2) Treatment Can Augment Immune Activation Without Enhancing Antitumor Activity in Renal Cell Carcinom. Cancer Investigation, 1991, 9, 35-48.	0.6	15
304	Regulation of Peripheral Catecholamine Responses to Acute Stress in Young Adult and Aged F-344 Rats. Stress, 1997, 2, 113-122.	0.8	15
305	Dopamine \hat{I}^2 -Hydroxylase Deficiency Associated with Mutations in a Copper Transporter Gene. Advances in Pharmacology, 1997, 42, 66-68.	1.2	15
306	Cardiac Uptake-1 Inhibition by High Circulating Norepinephrine Levels in Patients with Pheochromocytoma. Hypertension, 2004, 43, 1227-1232.	1.3	15

#	Article	IF	Citations
307	Functional Neuroimaging of Sympathetic Innervation of the Heart. Annals of the New York Academy of Sciences, 2004, 1018, 231-243.	1.8	15
308	Attenuated Preâ€ejection Period Response to Tyramine in Patients with Cardiac Sympathetic Denervation. Annals of the New York Academy of Sciences, 2008, 1148, 486-489.	1.8	15
309	The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein. Neuroscience Letters, 2015, 590, 134-137.	1.0	15
310	Spectrum of abnormalities of sympathetic tyrosine hydroxylase and alpha-synuclein in chronic autonomic failure. Clinical Autonomic Research, 2018, 28, 223-230.	1.4	15
311	Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society. Clinical Autonomic Research, 2020, 30, 13-18.	1.4	15
312	Cardiac <scp>¹⁸Fâ€Dopamine PET</scp> Distinguishes <scp>PD</scp> with Orthostatic Hypotension from Parkinsonian <scp>MSA</scp> . Movement Disorders Clinical Practice, 2021, 8, 582-586.	0.8	15
313	Plasma catecholamines and renin during operant blood pressure conditioning in baboons. Physiology and Behavior, 1981, 26, 33-37.	1.0	14
314	Skin color, aging, and plasma l-dopa levels. Journal of the Autonomic Nervous System, 1989, 26, 261-263.	1.9	14
315	Neurotransmitters and stress. Biofeedback and Self-regulation, 1990, 15, 243-271.	0.3	14
316	Monoaminergic Effects of Folinic Acid, <scp> </scp> â€DOPA, and 5â€Hydroxytryptophan in Dihydropteridine Reductase Deficiency. Journal of Neurochemistry, 1995, 64, 2810-2813.	2.1	14
317	Failure of propranolol to prevent tilt-evoked systemic vasodilatation, adrenaline release and neurocardiogenic syncope. Clinical Science, 2006, 111, 209-216.	1.8	14
318	Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel–Lindau syndrome. Journal of Endocrinology, 2007, 193, 225-233.	1.2	14
319	Pleiotropic neuropathological and biochemical alterations associated with Myo5a mutation in a rat Model. Brain Research, 2018, 1679, 155-170.	1.1	14
320	Peripheral synucleinopathy in a DJ1 patient with Parkinson disease, cataracts, and hearing loss. Neurology, 2019, 92, 1113-1115.	1.5	14
321	Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies. Journal of Neurochemistry, 2021, 158, 554-568.	2.1	14
322	Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans. Clinical Pharmacology and Therapeutics, 2004, 76, 480-489.	2.3	13
323	Clinical Catecholamine Neurochemistry: A Legacy of Julius Axelrod. Cellular and Molecular Neurobiology, 2006, 26, 693-700.	1.7	13
324	Plasma Catechols in Familial Dysautonomia: A Long-term Follow-up Study. Neurochemical Research, 2008, 33, 1889-1893.	1.6	13

#	Article	IF	Citations
325	The "Sick-but-not-Dead―Phenomenon Applied to Catecholamine Deficiency in Neurodegenerative Diseases. Seminars in Neurology, 2020, 40, 502-514.	0.5	13
326	Estimation of striatal dopamine spillover and metabolism in vivo. NeuroReport, 2000, 11, 3367-3373.	0.6	12
327	Cerebrospinal fluid levels of catechols in patients with neurogenic orthostatic hypotension. Clinical Science, 2003, 104, 649-654.	1.8	12
328	What ARE Parkinson disease? Non-motor features transform conception of the shaking palsy. Neurobiology of Disease, 2012, 46, 505-507.	2.1	12
329	Lâ€Threoâ€Dihydroxyphenylserine corrects neurochemical abnormalities in a menkes disease mouse model. Annals of Neurology, 2013, 73, 259-265.	2.8	12
330	Quantitative indices of baroreflex-sympathoneural function: application to patients with chronic autonomic failure. Clinical Autonomic Research, 2014, 24, 103-110.	1.4	12
331	Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson's disease through mitochondrial dysfunction. PLoS Genetics, 2020, 16, e1008868.	1.5	12
332	Pathophysiological significance of increased α-synuclein deposition in sympathetic nerves in Parkinson's disease: a post-mortem observational study. Translational Neurodegeneration, 2022, 11, 15.	3.6	12
333	Human recombinant interferon-?SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse. Breast Cancer Research and Treatment, 1993, 25, 141-150.	1.1	11
334	Triiodothyronine attenuates estradiol-induced increases in dopamine D-2 receptor number in rat anterior pituitary. Brain Research, 1996, 712, 148-152.	1.1	11
335	Catecholamine Phenotyping: Clues to the Diagnosis, Treatment, and Pathophysiology of Neurogenetic Disorders. Journal of Neurochemistry, 2002, 67, 1781-1790.	2.1	11
336	Painful sweating. Neurology, 2004, 63, 1471-1475.	1.5	11
337	Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia. Psychopharmacology, 2004, 176, 369-375.	1.5	11
338	Dopamine Contamination of Infused Tyramine. Clinical Chemistry, 2005, 51, 1733-1735.	1.5	11
339	Contamination of the Norepinephrine Prodrug Droxidopa by Dihydroxyphenylacetaldehyde. Clinical Chemistry, 2010, 56, 832-838.	1.5	11
340	<scp>αâ€Synuclein</scp> Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease. Movement Disorders, 2021, 36, 2346-2357.	2.2	11
341	Haemodynamic actions of insulin. Current Opinion in Nephrology and Hypertension, 1998, 7, 99-106.	1.0	10
342	Local sympathetic function in human skeletal muscle and adipose tissue assessed by microdialysis. Clinical Autonomic Research, 2002, 12, 13-19.	1.4	10

#	Article	IF	Citations
343	Diagnosis of Copper Transport Disorders. , 2011, Chapter 17, Unit17.9.		10
344	Carotid artery thickening and neurocirculatory abnormalities in de novo Parkinson disease. Journal of Neural Transmission, 2014, 121, 1259-1268.	1.4	10
345	Renal Effects of L-DOPA in Heart Failure. Journal of Cardiovascular Pharmacology, 1999, 33, 922-928.	0.8	10
346	Threshold for adrenomedullary activation and increased cardiac work during mild core hypothermia. Clinical Science, 2002, 102, 119-25.	1.8	10
347	Applied developmental psychology: Problems and prospects for an emerging discipline. Journal of Applied Developmental Psychology, 1983, 4, 341-348.	0.8	9
348	Simultaneous determination of endogenous catechols and exogenous 2- and 6-fluorinated catechols in tissue and plasma using liquid chromatography with electrochemical detection. Biomedical Applications, 1988, 431, 156-162.	1.7	9
349	Sex, Handedness and Allergy: Are They Related to Academic Giftedness?. Journal for the Education of the Gifted, 1991, 14, 412-422.	0.5	9
350	A new sign of sympathetic neurocirculatory failure: premature ventricular contraction as a "one-beat Valsalva maneuver― Clinical Autonomic Research, 2000, 10, 63-67.	1.4	9
351	THE EFFECT OF DOCARPAMINE, A DOPAMINE PRO-DRUG, ON BLOOD PRESSURE AND CATECHOLAMINE LEVELS IN SPONTANEOUSLY HYPERTENSIVE RATS. Clinical and Experimental Hypertension, 2000, 22, 419-429.	0.5	9
352	Plasma biomarkers of decreased vesicular storage distinguish Parkinson disease with orthostatic hypotension from the parkinsonian form of multiple system atrophy. Clinical Autonomic Research, 2015, 25, 61-67.	1.4	9
353	Cardiac sympathetic innervation and vesicular storage in pure autonomic failure. Annals of Clinical and Translational Neurology, 2020, 7, 1908-1918.	1.7	9
354	The wisdom of the body revisited: the adrenomedullary response to mild core hypothermia in humans. Endocrine Regulations, 2001, 35, 3-7.	0.5	9
355	Quantitative protein changes in metastatic versus primary epithelial ovarian carcinoma. Gynecologic Oncology, 1991, 41, 22-27.	0.6	8
356	Advances in drug delivery and targeting. Current Opinion in Oncology, 1991, 3, 1096-1104.	1.1	8
357	Functional α3-glycine receptors in rat adrenal. European Journal of Pharmacology, 1995, 288, 399-401.	2.7	8
358	Association of innervation-adjusted alpha-synuclein in arrector pili muscles with cardiac noradrenergic deficiency in autonomic synucleinopathies. Clinical Autonomic Research, 2019, 29, 587-593.	1.4	8
359	Different phenoconversion pathways in pure autonomic failure with versus without Lewy bodies. Clinical Autonomic Research, 2021, 31, 677-684.	1.4	8
360	The rat rotenone model reproduces the abnormal pattern of central catecholamine metabolism found in Parkinson's disease. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	8

#	Article	IF	CITATIONS
361	Neural circulatory control in the hyperdynamic circulatory state syndrome. American Heart Journal, 1985, 109, 387-390.	1.2	7
362	Species-dependent differences in recovery of 3,4-dihydroxybenzylamine in assays of plasma catecholamines. Biomedical Applications, 1988, 430, 123-127.	1.7	7
363	Plasma levels of catechols after fasting in intact or adrenal-demedullated rats. Journal of the Autonomic Nervous System, 1989, 26, 181-184.	1.9	7
364	Plasma catecholamine, renin activity, and ACTH responses to the serotonin receptor agonist DOI in juvenile spontaneously hypertensive rats. Life Sciences, 1993, 53, 1573-1582.	2.0	7
365	Plasma sulfoconjugated dopamine levels are normal in patients with autonomic failure. Translational Research, 1996, 128, 488-491.	2.4	7
366	On the Dialectic Between Molecular Biology and Integrative Physiology: Toward a New Medical Science. Perspectives in Biology and Medicine, 1997, 40, 505-515.	0.3	7
367	Autonomic dysfunction in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 343-363.	1.0	7
368	Temporary elimination of orthostatic hypotension by norepinephrine infusion. Clinical Autonomic Research, 2012, 22, 303-306.	1.4	7
369	Adrenomedullary Response to Glucagon in Patients with Primary Sjögren's Syndrome. Cellular and Molecular Neurobiology, 2012, 32, 903-906.	1.7	7
370	Evidence of Reduced Efferent Renal Sympathetic Innervation After Chemical Renal Denervation in Humans. American Journal of Hypertension, 2021, 34, 744-752.	1.0	7
371	Substantial renal conversion of l-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension. Clinical Autonomic Research, 2019, 29, 113-117.	1.4	6
372	Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society. Autonomic Neuroscience: Basic and Clinical, 2020, 223, 102550.	1.4	6
373	Pheochromocytoma: Rediscovery as a Catecholamine-Metabolizing Tumor. Endocrine Pathology, 2003, 14, 193-212.	5.2	6
374	Sex-Specific Alterations in Dopamine Metabolism in the Brain after Methamphetamine Self-Administration. International Journal of Molecular Sciences, 2022, 23, 4353.	1.8	6
375	On the existence of functional beta-adrenoceptors on vascular sympathetic nerve endings in the human forearm. Journal of Hypertension, 1994, 12, 681???690.	0.3	5
376	"Sick-but-not-dead― multiple paths to catecholamine deficiency in Lewy body diseases. Stress, 2020, 23, 633-637.	0.8	5
377	Do indices of baroreflex failure and peripheral noradrenergic deficiency predict the magnitude of orthostatic hypotension in Lewy body diseases?. Clinical Autonomic Research, 2021, 31, 543-551.	1.4	5
378	Dietary Salt Intake and the Clonidine Suppression Test. Journal of Clinical Pharmacology, 1987, 27, 199-205.	1.0	4

#	Article	IF	CITATIONS
379	A phase II study of crisnatol mesylate in patients with ovarian carcinoma. Investigational New Drugs, 1992, 10, 107-112.	1.2	4
380	Cardiovascular Autonomic Dysfunction. , 2005, , 149-157.		4
381	AUTONOMIC FAILURE IN NEURODEGENERATIVE DISORDERS. CONTINUUM Lifelong Learning in Neurology, 2007, 13, 111-142.	0.4	4
382	Genotype and Vascular Phenotype Linked by Catecholamine Systems. Circulation, 2008, 117, 458-461.	1.6	4
383	Simultaneous Liquid-Chromatographic Determination of Plasma Catecholamines and Metabolites. Clinical Chemistry, 2009, 55, 2223-2224.	1.5	4
384	Cardiac Sympathetic Neuroimaging in Dementia with Lewy Bodies. Journal of Neuroimaging, 2012, 22, 109-110.	1.0	4
385	Cardiovascular Autonomic Dysfunction in Parkinson's Disease. , 2013, , 201-212.		4
386	Molecular and biochemical characterization of Mottled-dappled, an embryonic lethal Menkes disease mouse model. Molecular Genetics and Metabolism, 2014, 113, 294-300.	0.5	4
387	Differential Susceptibilities of Catecholamines to Metabolism by Monoamine Oxidases. Journal of Pharmacology and Experimental Therapeutics, 2021, 379, 253-259.	1.3	4
388	What new can we learn from cardiac sympathetic neuroimaging in synucleinopathies?. Clinical Autonomic Research, 2022, 32, 95-98.	1.4	4
389	Modeling the Progression of Cardiac Catecholamine Deficiency in Lewy Body Diseases. Journal of the American Heart Association, 2022, 11, .	1.6	4
390	Prolonged changes in plasma concentrations of catecholamine metabolites following a single infusion of an MPTP analog. Life Sciences, 1990, 47, 1895-1901.	2.0	3
391	Sympathoneural and skeletal muscle contributions to plasma DOPA responses in pithed rats. Journal of the Autonomic Nervous System, 1991, 35, 169-174.	1.9	3
392	Method for measuring endogenous 3-O-methyldopa in urine and plasma. Biomedical Applications, 1991, 568, 45-54.	1.7	3
393	CLINICAL EVALUATION OF THE AUTONOMIC NERVOUS SYSTEM. CONTINUUM Lifelong Learning in Neurology, 2007, 13, 33-49.	0.4	3
394	Hypertension Increases Cerebral 6- ¹⁸ F-Fluorodopaâ€"Derived Radioactivity. Journal of Nuclear Medicine, 2009, 50, 1479-1482.	2.8	3
395	Systemic hemodynamics during orthostasis in multiple system atrophy. Parkinsonism and Related Disorders, 2016, 25, 106-107.	1.1	3
396	Multiple catechols in human plasma after drinking caffeinated or decaffeinated coffee. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1185, 122988.	1,2	3

#	Article	IF	CITATIONS
397	Effects of hypercortisolemia or hyperinsulinemia on neurochemical indices of catecholamine release and synthesis in conscious rats. Journal of the Autonomic Nervous System, 1995, 54, 104-112.	1.9	2
398	Hereditary dysautonomias: current knowledge and collaborations for the future. Clinical Autonomic Research, 2003, 13, 180-195.	1.4	2
399	Coronary vascular resistance in primary chronic autonomic failure. Clinical Autonomic Research, 2006, 16, 293-295.	1.4	2
400	Autonomic function tests: introduction to the series. Clinical Autonomic Research, 2017, 27, 141-143.	1.4	2
401	Is pure autonomic failure a distinct nosologic entity?. Clinical Autonomic Research, 2017, 27, 121-122.	1.4	2
402	Plasma Catechols After Eating Olives. Clinical and Translational Science, 2018, 11, 32-37.	1.5	2
403	NEONATOLOGY FRIDAY, MAY 29TH, 1987 SOUTH BALLROOM 10. Critical Care Medicine, 1987, 15, 436.	0.4	1
404	Antihypertensive Therapy with Ketanserin. Journal of Cardiovascular Pharmacology, 1988, 12, 384-389.	0.8	1
405	Induction of reversible growth retardation and growth hormone deficiency by blockade of norepinephrine synthesis in the rat. European Journal of Endocrinology, 1993, 129, 554-558.	1.9	1
406	The Sympathetic Nervous and the Adrenomedullary Hormonal Systems: Differential Responses to Stressors. Journal of Musculoskeletal Pain, 1998, 6, 63-68.	0.3	1
407	Prevalence of anti-locus coeruleus immunoreactivity in CSF of patients with autonomic failure. Clinical Autonomic Research, 2006, 16, 401-405.	1.4	1
408	Noradrenergic Neurotransmission. , 2012, , 37-43.		1
409	Irwin J Kopin. Neuropsychopharmacology, 2017, 42, 2656-2656.	2.8	1
410	Response to: Human papillomavirus (HPV) vaccine safety concerning POTS, CRPS and related conditions. Clinical Autonomic Research, 2020, 30, 183-184.	1.4	1
411	Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension. Clinical Autonomic Research, 2021, 31, 351-353.	1.4	1
412	'Sick But Not Dead': Multiple Denervation-Independent Abnormalities of Myocardial Noradrenergic Function in Lewy Body Diseases. SSRN Electronic Journal, 0, , .	0.4	1
413	THE ROLE OF ATRIAL NATRIURETIC PEPTIDE IN CONGENITAL HEART DISEASE. Critical Care Medicine, 1987, 15, 413.	0.4	O
414	Down-regulation of an abundant cellular protein associated with tumor progression. Carcinogenesis, 1988, 9, 2129-2132.	1.3	0

#	Article	IF	CITATIONS
415	The Doctor's Dilemma (The Nurse's Waterloo). Cancer Investigation, 1988, 6, 361-363.	0.6	O
416	Novel Catecholaminergic Systems. Advances in Pharmacology, 1997, 42, 819-824.	1.2	0
417	Compression of Liver Parenchyma by A Malignant Hepatic Cyst: A Previously Unreported Manifestation of Metastatic Gastric Cancer. American Journal of Gastroenterology, 2003, 98, 1211-1213.	0.2	O
418	INTRODUCTION TO THE SALSA, A SALTDOME SHOWER ARRAY AS A GZK NEUTRINO OBSERVATORY. International Journal of Modern Physics A, 2006, 21, 252-253.	0.5	0
419	Patients as a Scientific Resource: Comments on Receiving the Ahrens Award. Clinical and Translational Science, 2011, 4, 231-232.	1.5	O
420	197. Survival, Growth, and Neurobehavioral Outcomes in a Mouse Model of Menkes Disease With CSF-Directed AAV9 and Subcutaneous Copper Histidine. Molecular Therapy, 2015, 23, S78.	3.7	0
421	Dopamine-Related Measurements From Both IPSC-Derived Dopaminergic Neurons and [18F]-FDOPA PET in Patients With Gaucher Disease With and Without Parkinsonism. Biological Psychiatry, 2020, 87, S164.	0.7	O
422	Pioneer Award Address: Ignorance isn't biased: Comments on receiving the Pioneer Award. Cleveland Clinic Journal of Medicine, 2009, 76, S31-S36.	0.6	0
423	Clinical Sympathetic Imaging. , 2012, , 399-403.		0
424	Cardiac Sympathetic Denervation. , 2014, , 133.		0